Tvardi TherapeuticsLTS:0HTC 12 Quick Ratio is 2.25 as of Mar. 2026, which is 35% below its 10-year median of 3.48. GuruFocus rates LTS:0HTC with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,412 Biotechnology companies, Tvardi Therapeutics ranks worse than 62.46% on this metric.
Tvardi Therapeutics has a quick ratio of 2.25. It generally indicates good short-term financial strength.
The historical rank and industry rank for Tvardi Therapeutics's Quick Ratio or its related term are showing as below:
LTS:0HTC'
s Quick Ratio Range Over the Past 10 Years
Min: 2.02 Med: 3.48 Max: 31.73
Current: 2.25
During the past 4 years, Tvardi Therapeutics's highest Quick Ratio was 31.73. The lowest was 2.02. And the median was 3.48.
LTS:0HTC's Quick Ratio is ranked worse than 62.46% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs LTS:0HTC: 2.25
Tvardi Therapeutics (LTS:0HTC) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Tvardi Therapeutics Quick Ratio Related Terms
Tvardi Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Tvardi Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HTC vs HOWL, TPST, XCUR: Quick Ratio Comparison
For the Biotechnology subindustry, Tvardi Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tvardi Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tvardi Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Tvardi Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Tvardi Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tvardi Therapeutics (LTS:0HTC) has a Quick Ratio of 2.25 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Tvardi Therapeutics and its competitors. This is 35% below median its historical median of 3.48. Over the past decade, Tvardi Therapeutics' Quick Ratio has ranged from 2.02 to 31.73. According to the industry distribution chart, Tvardi Therapeutics ranks #882 out of 1412 companies in the Biotechnology industry, placing it in the top 62.5%.
Is Tvardi Therapeutics' Quick Ratio too high?
Tvardi Therapeutics' current Quick Ratio of 2.25 is 35% below median its 10-year median of 3.48. Over the past 10 years, this metric has ranged from a low of 2.02 to a high of 31.73. The Biotechnology industry median Quick Ratio is 3.60. Tvardi Therapeutics' value of 2.25 is 37.5% below this industry median. Based on the distribution chart, Tvardi Therapeutics ranks #882 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Tvardi Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' Quick Ratio compare to HOWL and TPST?
According to the Biotechnology industry distribution chart, Tvardi Therapeutics ranks #882 out of 1412 companies for Quick Ratio. This places Tvardi Therapeutics in the lower half of its industry. The industry median Quick Ratio is 3.60. Tvardi Therapeutics' value of 2.25 is 37.5% below this benchmark. Historically, Tvardi Therapeutics' own Quick Ratio has ranged from 2.02 to 31.73 over the past decade. While the company's 10-year median is 3.48 vs. the industry median of 3.60, Tvardi Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tvardi Therapeutics's current Quick Ratio of 2.25 is 37.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Tvardi Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tvardi Therapeutics's current Quick Ratio is 2.25, which is 35% below median its own 10-year median of 3.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (LTS:0HTC) has a current Quick Ratio of 2.25. The current Quick Ratio is 2.25, which is 35% below median its 10-year median of 3.48 and 37.5% below the Biotechnology industry median of 3.60. Tvardi Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current Quick Ratio is 2.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HTC has been successfully added to your 